RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > 2022 > 3 > Recon: FDA approves J&J and Legend’s CAR-T cancer therapy; Gilead lands CRL for HIV drug over glass

Recon: FDA approves J&J and Legend’s CAR-T cancer therapy; Gilead lands CRL for HIV drug over glass vial concerns

Posted 01 March 2022 | By Joanne S. Eglovitch 

Recon: FDA approves J&J and Legend’s CAR-T cancer therapy; Gilead lands CRL for HIV drug over glass vial concerns

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.

In Focus: US
  • 'We are ready to go': FDA OKs J&J and Legend's BCMA CAR-T, setting stage for showdown with Bristol Myers (Endpoints) (Fierce) (STAT) (Reuters)
  • Breakthrough gene-editing technology belongs to Harvard, MIT -U.S. tribunal (Reuters)
  • U.S. FDA extends review period for expanded use of Abbvie's psoriasis drug (Reuters)
  • FDA rejects Gilead’s next big HIV drug over glass vial issues (Endpoints) (Reuters)
  • Pfizer Covid vaccine is less effective in kids 5 to 11, study finds (STAT) (Reuters) (NYT)
  • FDA approves CTI BioPharma's bone marrow cancer drug (Reuters) (FDA)
  • Novavax expects to apply for full approval of COVID vaccine in H2 (Reuters)
  • FDA Warns Against Using Certain Celltrion Covid Tests (Bloomberg)
  • BMS ‘Slow-Rolled’ Approval of Liso-Cel, Investors Claim, Citing Timeline Of Other CAR-T Therapies (The Pink Sheet)
  • Pfizer fails phase 3 C. diff vaccine test but still spies possible path forward (Fierce)
  • Biden’s State Of The Union Will Mention Drug Prices, But Not Outline Any New Plans (The Pink Sheet) (Inside Health Policy)
  • Warren, 12 other U.S. lawmakers press drugs lobby group on price increases (Reuters)
In Focus: International
  • Sputnik: COVID-19 Vaccine Caught Up in Sanctions On Russia Over Ukraine Invasion (The Pink Sheet) (Bloomberg)
  • AstraZeneca, Swiss firm Neurimmune ink $760 million deal for antibody drug (Reuters)
  • DARWIN EU: The Go-To Place For Real World Data (The Pink Sheet)
  • China Proposes Rolling Submissions For Innovative New Drugs (The Pink Sheet)
  • Bayer CEO Outlines Action In Aftermath Of Ukraine Invasion (Scrip)
  • Indonesia extends AstraZeneca vaccine shelf life as 6 mln doses near expiry (Reuters)
Pharma & Biotech
  • AbbVie adds to its neuro pipeline with a $1B buyout deal, bolting on a new drug aimed at Alzheimer’s (Endpoints)
  • 2021’s top clinical trial flops (Fierce)
  • Ants, spiders, and mold: Why a big compounding pharmacy recently recalled all its products (STAT)
  • In the wake of patient death, Sutro says its Chinese partner is rethinking their deal and withholding $40M (Endpoints)
  • Sanofi, Regeneron build their case for yet another approval for immunology star Dupixent (Endpoints)
  • As Eli Lilly steams ahead with a closely-watched BTK drug, its rivals at Merck are taking a $275M write-down on delay (Endpoints)
  • Pfizer and Alvotech look to interchangeability to stand out in a crowded Humira biosimilar field (Endpoints)
  • Emergent's troubled Baltimore site gets $100M upgrade (Endpoints)
Medtech
  • FDA's performance against MDUFA IV decision goal falls to new low (MedTech Dive)
  • European Regulatory Roundup February 2022: Major Push Now On IVD Regulation Preparedness (MedTech Insight)
  • Medtech, hospitals on alert for cyberattacks after Russia's invasion of Ukraine (MedTech Dive)
  • FDA Stresses Need For Routine Monitoring Of Endovascular Aortic Repair Patients (MedTech Insight)
  • Boston Scientific touts early results of real-world Watchman FLX study (MedTech Dive)
Government, Regulatory & Legal
  • Endo Held Liable in Opioid Case Via Default Judgment (Bloomberg)
  • Diabetes Drugmakers Seek Judgment After Plaintiffs’ Expert Axed (Bloomberg)
  • Eli Lilly Whistleblower Advances Medicaid Drug Suit Toward Trial (Bloomberg)
  • Justices Probe Proof Burden in ‘Pill Mill’ Prosecutions (Bloomberg)
  • HHS sets out plans to make medical device, diagnostics supply chains pandemic-proof (MedTech Dive)
Regulatory Recon is our daily intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe.
 
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.

 

© 2022 Regulatory Affairs Professionals Society.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe